24 May 2021
Aerodyne Group, a top-tier global drone services company headquartered in Malaysia, AI and Robotics Ventures Company Limited (ARV), a subsidiary of PTTEP, and Digital Creation Co., Ltd. (DC) announced the launch of a joint venture company ‘AeroSky (Thailand) Company Limited’ which will provide state-of-the-art drone-based enterprise solutions across the Thai market.
AeroSky, a new joint venture for drone solutions, capitalizes on the digital transformation trend and opportunities. To provide unparalleled services to clients in the telecoms, electricity, oil & gas, and other infrastructure-led industries, the business will combine core strengths of ARV’s expertise in the provision of drones and sophisticated AI and Robotic solutions, Aerodyne Group’s integrated drone and software-as-a-service solutions, and DC’s leading-edge machine learning and monitoring technologies.
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand The leading Australian CRO Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.
BriefingWire.com, 5/09/2021 - ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.
Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand
ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.
Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).
This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).
Avance Clinical to Present Decentralized Trials - No Going Back for Oracle Health Sciences Connect
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference.
Avance Clinical CEO Yvonne Lungershausen, shared the company s insights on the future of Decentralized Clinical Trials (DCTs) and the technology and patient factors that will determine success. Avance Clinical uses the full range of eClincial technologies to support clients wanting DCTs or a site-based approach while still leveraging advance technology including ePro, eSource and eConsent.
ADELAIDE, AU, Apr 22, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference.
Title: Decentralized Trials - No Going Back
Link: https://www.oracle.com/in/industries/life-sciences/health-sciences-connect/sessions/
Time: 23 April, 2021 - 3.05 pm (Australia/Adelaide ACST).
Avance Clinical CEO Yvonne Lungershausen, shared the company s insights on the future of Decentralized Clinical Trials (DCTs) and the technology and patient factors that will determine success. Avance Clinical uses the full range of eClincial technologies to support clients wanting DCTs or a site-based approach while still leveraging advance technology including ePro, eSource and eConsent.